Established in 2006, the mission of the BARDA is to develop and procure medical countermeasures, vaccines, drugs, therapeutics, diagnostic tools, and nonpharmaceutical products, that address the public health and medical consequences of chemical, biological, radiological, and nuclear (CBRN) accidents, incidents, and attacks, pandemic influenza, and emerging infectious diseases. Specifically, BARDA supports the advanced development and procurement of drugs, vaccines, and other products that are considered priorities for responding to and recovering from threats to American national health security. To date, the medical countermeasures and products in this diverse portfolio have received a total of 61 FDA approvals, licensures, or clearances..
For more information or if you wish to make an appointment, please email alexei_teague@uml.edu